» Articles » PMID: 2846658

Mechanisms Underlying Transition from Acute Glomerular Injury to Late Glomerular Sclerosis in a Rat Model of Nephrotic Syndrome

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1988 Nov 1
PMID 2846658
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Functional and morphologic measurements were performed in Munich-Wistar rats after a single central venous injection of puromycin aminonucleoside (PA) or saline vehicle (sham). During phase I, PA rats exhibited overt nephrotic syndrome and impaired glomerular filtration, primarily due to a reduction in the glomerular capillary ultrafiltration coefficient. The morphologic counterpart of the latter consisted of effacement of glomerular epithelial cell foot processes and decrease in the number of filtration slit diaphragms. Administration of the angiotensin I converting enzyme inhibitor (CEI) enalapril to PA rats did not ameliorate glomerular dysfunction. During phase II, PA rats exhibited spontaneous resolution of proteinuria, impaired function, and morphologic abnormalities. However, PA rats now demonstrated marked glomerular capillary hypertension and continued, albeit lesser, reductions in the ultrafiltration coefficient. Concurrent CEI administration modestly lowered systemic arterial pressure, and normalized the glomerular capillary hydraulic pressure and ultrafiltration coefficient. Additional rats were studied during phase III, 70 wk after injection. In PA rats, prior glomerular hypertension was associated with development of recurrent proteinuria and extensive glomerular sclerosis, whereas concurrent CEI administration limited these parameters to values comparable to those in sham rats. Glomerular hypertension thus may explain the development of glomerular sclerosis and renal failure long after an episode of acute glomerular injury.

Citing Articles

Angiotensin II-independent abnormal renal vascular reactivity during puromycin nephropathy.

Juncos L, Adeoye A, Martin F, Juncos J, Baigorria S, Garcia N J Med Life. 2024; 17(3):309-313.

PMID: 39044930 PMC: 11262600. DOI: 10.25122/jml-2023-0367.


Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis.

Salfi G, Casiraghi F, Remuzzi G Front Immunol. 2023; 14:1247606.

PMID: 37795085 PMC: 10546017. DOI: 10.3389/fimmu.2023.1247606.


Renal Inflammation and Innate Immune Activation Underlie the Transition From Gentamicin-Induced Acute Kidney Injury to Renal Fibrosis.

Albino A, Zambom F, Foresto-Neto O, Oliveira K, Avila V, Arias S Front Physiol. 2021; 12:606392.

PMID: 34305624 PMC: 8293269. DOI: 10.3389/fphys.2021.606392.


Association of Proteinuria with Urinary Concentration Defect in Puromycin Aminonucleoside Nephrosis.

Jo C, Kim S, Kim G Electrolyte Blood Press. 2021; 18(2):31-39.

PMID: 33408745 PMC: 7781767. DOI: 10.5049/EBP.2020.18.2.31.


Trpc6 inactivation confers protection in a model of severe nephrosis in rats.

Kim E, Yazdizadeh Shotorbani P, Dryer S J Mol Med (Berl). 2018; 96(7):631-644.

PMID: 29785489 PMC: 6015123. DOI: 10.1007/s00109-018-1648-3.


References
1.
Corman B, Michel J . Renin-angiotensin system, converting-enzyme inhibition and kidney function in aging female rats. Am J Physiol. 1986; 251(3 Pt 2):R450-5. DOI: 10.1152/ajpregu.1986.251.3.R450. View

2.
Weinberger M . Antihypertensive therapy and lipids. Evidence, mechanisms, and implications. Arch Intern Med. 1985; 145(6):1102-5. View

3.
GLASSER R, Velosa J, Michael A . Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest. 1977; 36(5):519-26. View

4.
Bohrer M, Baylis C, ROBERTSON C, Brenner B, Troy J, Willis W . Mechanisms of the puromycin-induced defects in the transglomerular passage of water and macromolecules. J Clin Invest. 1977; 60(1):152-61. PMC: 372353. DOI: 10.1172/JCI108751. View

5.
Rodriguez-Iturbe B, Herrera J, Garcia R . Response to acute protein load in kidney donors and in apparently normal postacute glomerulonephritis patients: evidence for glomerular hyperfiltration. Lancet. 1985; 2(8453):461-4. DOI: 10.1016/s0140-6736(85)90399-x. View